Overview

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-12
Target enrollment:
Participant gender:
Summary
This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI 30 kg/m) or who are overweight (BMI 27 kg/m) with at least one weight-related comorbidity. RGT001-075 or matching placebo will be administered once daily.
Phase:
PHASE2
Details
Lead Sponsor:
Regor Pharmaceuticals Inc.